Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE014 (NLD) (Dr. Moreau)
· consented 2023-05-11
Adverse events
4
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-07-19 (study day 55); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-07-23 (study day 59); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-08-11 (study day 78); relationship: not assessed; serious criteria: hospitalization
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-01-14 (study day 234); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.